dantrolene has been researched along with Brain Disorders in 5 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A fever of unknown origin developed in a patient with sequelae of acute encephalopathy who had received dantrolene for severe spasticity." | 3.74 | [Recurrent fever related to dantrolene sodium in a girl with sequelae of acute encephalopathy]. ( Fujikawa, Y; Komaki, H; Nakagawa, E; Oomi, T; Sasaki, M; Sugai, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Muehlschlegel, S | 1 |
| Sims, JR | 1 |
| Narumi, Y | 1 |
| Shiihara, T | 1 |
| Yoshihashi, H | 1 |
| Sakazume, S | 1 |
| van der Knaap, MS | 1 |
| Nishimura-Tadaki, A | 1 |
| Matsumoto, N | 1 |
| Fukushima, Y | 1 |
| Oomi, T | 1 |
| Nakagawa, E | 1 |
| Fujikawa, Y | 1 |
| Komaki, H | 1 |
| Sugai, K | 1 |
| Sasaki, M | 1 |
| Berg, M | 1 |
| Bruhn, T | 1 |
| Frandsen, A | 1 |
| Schousboe, A | 1 |
| Diemer, NH | 1 |
| Burke, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dantrolene in the Treatment of Cerebral Vasospasm After Subarachnoid Hemorrhage - a Phase 1 Study[NCT00964548] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Dantrolene in the Prevention and Treatment of Cerebral Vasospasm in Subarachnoid Hemorrhage[NCT01024972] | Phase 1/Phase 2 | 31 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Systolic Blood Pressure (Change from baseline systolic blood pressure (pre-infusion) over time until 135 minutes post-infusion). (NCT00964548)
Timeframe: baseline until 135 minutes post-infusion
| Intervention | mmHg (Mean) |
|---|---|
| Dantrolene (Low Dose) | -8 |
| Dantrolene (High Dose) | -3.4 |
Mean flow velocities of vessel in vasospasm (Change from baseline mean flow velocity (pre-infusion) over time until 135 minutes post-infusion). (NCT00964548)
Timeframe: baseline until 135 minutes post-infusion
| Intervention | cm/s (Mean) |
|---|---|
| Dantrolene (Low Dose) | -18 |
| Dantrolene (High Dose) | -13 |
Peak Systolic Velocity of vessel in vasospasm (Change from baseline peak systolic velocity (pre-infusion) over time until 135 minutes post-infusion). (NCT00964548)
Timeframe: baseline until 135 minutes post-infusion
| Intervention | cm/s (Mean) |
|---|---|
| Dantrolene (Low Dose) | -30 |
| Dantrolene (High Dose) | -26 |
Number of subjects who developed hyponatremia (sNa ≤132mmol/L) (NCT01024972)
Timeframe: Seven days
| Intervention | participants (Number) |
|---|---|
| Dantrolene | 7 |
| Placebo | 10 |
Number of subjects who expired during hospitalization. (NCT01024972)
Timeframe: up to 90 days
| Intervention | participants (Number) |
|---|---|
| Dantrolene | 2 |
| Placebo | 1 |
Number of subjects who developed liver toxicity as evidenced by Liver Function Test elevation greater than 5 times the upper limit of normal. (NCT01024972)
Timeframe: 7 days
| Intervention | participants (Number) |
|---|---|
| Dantrolene | 1 |
| Placebo | 0 |
1 review available for dantrolene and Brain Disorders
| Article | Year |
|---|---|
Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit.
Topics: Brain Diseases; Calcium; Critical Care; Dantrolene; Humans; Muscle Relaxants, Central; Ryanodine Rec | 2009 |
Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit.
Topics: Brain Diseases; Calcium; Critical Care; Dantrolene; Humans; Muscle Relaxants, Central; Ryanodine Rec | 2009 |
Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit.
Topics: Brain Diseases; Calcium; Critical Care; Dantrolene; Humans; Muscle Relaxants, Central; Ryanodine Rec | 2009 |
Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit.
Topics: Brain Diseases; Calcium; Critical Care; Dantrolene; Humans; Muscle Relaxants, Central; Ryanodine Rec | 2009 |
4 other studies available for dantrolene and Brain Disorders
| Article | Year |
|---|---|
Hypomyelination with atrophy of the basal ganglia and cerebellum in an infant with Down syndrome.
Topics: Atrophy; Basal Ganglia; Brain Diseases; Cerebellum; Dantrolene; Down Syndrome; Humans; Infant; Magne | 2011 |
[Recurrent fever related to dantrolene sodium in a girl with sequelae of acute encephalopathy].
Topics: Acute Disease; Brain Diseases; Dantrolene; Female; Fever of Unknown Origin; Humans; Infant; Muscle R | 2007 |
Kainic acid-induced seizures and brain damage in the rat: role of calcium homeostasis.
Topics: Animals; Behavior, Animal; Body Temperature; Brain Diseases; Calcium; Calcium Channels; Dantrolene; | 1995 |
An approach to the treatment of spasticity.
Topics: Adrenergic alpha-Antagonists; Baclofen; Brain Diseases; Dantrolene; Diazepam; Humans; Mephenesin; Mu | 1975 |